Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharma GmbH
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 4 ans
Investigation of renal tolerability, efficacy and safety of a CNI-free regimen versus a low-dose CNI- regimen in de novo heart transplant recipients
The primary objective of this trial is to demonstrate superiority of a CNI-free regimen with respect to the renal function at Month 18 post Tx assessed by glomerular filtration rate – MDRD method – as...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 4 ans
Comparison of the long-term efficacy and safety of Lucentis versus Ozurdex in patients with visual impairment due to macular edema following retinal vein occlusion (central or branch vein) who have completed the respective core study (CRFB002EDE17 or CRFB002EDE18)
The primary objective is to evaluate the ocular and non-ocular adverse events during the 6-months study period in patients treated with Lucentis (0.5 mg) vs. treated with Ozurdex
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 4 ans
An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the single pill (SPC) combination of Aliskiren 300 mg / Amlodipine 10 mg in hypertensive patients not adequately respond to an uptitrated 4 week therapy with the SPC of Olmesartan 40 mg / Amlodipine 10 mg, with a potential extention if patients still not adequately respond with a 4 week therapy with the SPC Aliskiren 300 mg / Amlodipine 10 mg / HCTZ 12,5 mg
To demonstrate that 4 weeks of treatment with SPC Aliskiren 300 mg / Amlodipine 10 mg at Visit 6 provide additional mean sitting diastolic blood pressure reduction in hypertensive patients not adequat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 4 ans
A 4 week, randomized, vehicle-controlled, multicenter evaluation of the efficacy and safety of 1% pimecrolimus cream in adult patients with perioral dermatitis followed by a 8 week treatment free observation phase in responders
To confirm the efficacy of pimecrolimus cream 1% in patients with perioral dermatitis, by testing the hypothesis that pimecrolimus cream 1% is superior in the mean reduction of the PODSI score (Perior...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 4 ans
Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients
To assess if a switch from MMF to myfortic® results in improved GI- and/or health-related quality of life outcomes, and to determine the proportion of liver transplant recipients who are experiencing ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 4 ans
Efficacy of everolimus on top to centre specific standard immunosuppressive regimen in lung transplant recipients
To demonstrate that an everolimus-based, quadruple immunosuppressive regimen has superior efficacy compared with a CNI-based triple immunosuppressive regimen on renal function as measured by cGFR acco...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 4 ans
An open phase III trial with Letrozole (Femara®) as Early Adjuvant treatment of postmenopausal patients with primary breast cancer
It is the aim of this prospective one arm phase III clinical study to evaluate recurrence in postmenopausal patients with breast cancer during 24 months of Letrozole treatment. · Rate of patients wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 4 ans
A randomized, double-blind, placebo controlled, multicenter, 3-period crossover study to compare the effect of indacaterol (150μg o.d.) on inspiratory capacity to placebo in patients with moderate COPD, using open label tiotropium (18μg o.d.) as active control
To demonstrate the superiority of indacaterol (150µg o.d.) compared to placebo with respect to Peak Inspiratory Capacity after 21 days of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 4 ans
An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of valsartan 160 mg plus HCTZ 25 mg in hypertensive patients not adequately responding to a 4 week therapy with the free combination of an angiotensin receptor blocker (candersartan 32 mg) plus HCTZ 25 mg
To demonstrate that 4 weeks of treatment with valsartan 160 mg plus HCTZ 25 mg in fixed dose combination provide an additional mean sitting diastolic blood pressure reduction in patients not adequatel...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 4 ans
Multicenter, triple-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tissue sarcomas
To evaluate preliminary efficacy of RAD001 in progressive or metastatic alveolar soft part sarcoma (ASPS). Efficacy is defined as the proportion of patients showing complete response, partial response...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
2
3
4
5
6
7
8
9
10
11
Suivant